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’INTRODUCTION
Glycogen is a complex branched polymer of glucose, with
R-(1,4) linear linkages and R-(1,6) branching linkages and a
broad distribution of molecular weights, ∼10
6 10
8 Da. Its
structure comprises diﬀerent hierarchical levels, from the indivi-
dual branches to the whole (branched) molecules that are
arranged as β particles (∼20 nm in size) and further into larger
Rparticles(∼10
2nminsize)intheliver.
1,2Thisisexempliﬁedin
the transmission electron micrograph in Figure 1A (obtained
using the techniques of Ryu et al.
3).
Theincidencesoftype2diabetesandofobesityareincreasing
dramatically worldwide. The basic characteristic of diabetes is
hyperglycemia: uncontrolled high glucose levels in the blood.
Liver glycogen acts as a blood-glucose buﬀer, being synthesized
in the liver when blood-glucose levels are high and quickly
degraded when blood-glucose levels are low, releasing glucose
into the blood.
4 This Communication uses advanced polymer
characterizationmethodstoexaminestructuraldiﬀerencesbetween
liver glycogen from db/db (a type-2 diabetic model) and from
healthy (þ/þ and db/þ) mice. The techniques used yield (i) the
so-called SEC weight distribution w(log Rh) of whole (branched)
molecules as functions of size (hydrodynamic radius Rh),
where w(log Rh) is the relative mass of whole glycogen molecules
whose size is given by log Rh, (ii) the weight-average molecular
weight (Mw) of the whole glycogen molecules, and (iii) the
number distribution Nde(X) of individual branches following
quantitativedegradation of the glycogen with debranchingenzyme
(the “chain-length distribution” (CLD) giving the relative number
of individual branches for each degree of polymerization X). The
normalizationsofw(logRh)a n dNde(X) arearbitrary. For a review
ofthesedistributions,see,forexample,ref5.Characterizationofthe
branched molecules is performed by size exclusion chromatogra-
phy(SEC) withdiﬀerential refractive indexdetection,giving w(log
Rh), and multiple-angle laser light scattering detection (MALLS),
which after integration of the signal over Rh yields Mw.T h eS E C
separation parameter is hydrodynamic volume Vh, with hydrody-
namic radius Rh from Vh =
4/3πRh
3. CLDs of the branches were
obtained using ﬂuorophore-assisted carbohydrate electrophoresis
6
(FACE).
’MATERIALS AND METHODS
Genetically diabetic C57BL/6J-db/db female mice were used in this
studyasamodelfortype2diabetes.Therecessivediabetic(db)genehas
a point mutation in the leptin receptor,
7 making db/db mice susceptible
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to suﬀer from obesity, transient hyperglycemia, hyperinsulinemia, and
hyperglucagonemia.
8 10Femalemicethatwereheterozygousforthedb
gene (db/þ), containing one wild-type and one mutated allele, and
homozygous with both wildtype alleles (þ/þ) were also analyzed.
Three age groups were used in this study. Adult mice were aged ∼3 and
4.5 months, and young mice were aged ∼1.5 months. Physiological
characteristics ofthediﬀerentanimal groupsaregiven inthe Supporting
Information (Table S1). All animal studies were performed in compli-
ance with the ethics committee of Wuhan University.
The procedure used here for liver-glycogen extraction and puriﬁca-
tionwithoutmoleculardegradationhasbeenpreviouslydescribed.
3The
SEC procedures, as detailed elsewhere,
11 used (methylsulﬁnyl)methane
(dimethylsulfoxide,DMSO)andLiBrassolventandeluent;thisensures
complete and molecularly dispersed dissolution. SEC ﬂow rates were
suchthatshearscissionofglycogen(whichisarelativelysmallmolecule)
was not a major eﬀect.
12 SEC recovery measured with starch in a similar
system is essentially 100%.
13 Enzymatic debranching and labeling for
FACE were performed using an established method.
6 FACE separation
and detection used anAppliedBiosystems (ABS, Foster City, CA) 3730
geneticanalyzerwitha50cmcapillaryarray.Labeleddebranchedmouse
glycogen samples were diluted by a factor of 10
4, and 20 μL of each
sample was loaded in each well. Samples were injected for 3 s and then
electrophoresed using 3730 buﬀer with EDTA (ABS) for a period of
5000satavoltageof15kVandacurrentof400mA.Datawerecollected
using Data Collection v3.0 software and were analyzed using Gene-
Mapper v3.7 software. The detection system was calibrated using the
ABS G5 dye set.
’RESULTS
Figure 1A C compares the SEC weight distributions of liver
glycogen from adult type 2 diabetic (db/db) and healthy mice
(db/þandþ/þ);becauseofSECcalibrationlimitations,theRh
axis above ∼50 nm is only semiquantitative.
12 Signiﬁcant diﬀer-
ences are seen between the size distributions of liver glycogen
from healthy mice compared with those from type 2 diabetic
mice(db/db).Thesediabetic/obeseglycogenparticlesarenever
as large as the largest nondiabetic glycogen and are narrowly
distributed, with a size range corresponding largely but not
exclusively to that of β particles. Healthy glycogen, however,
covers a larger size range, including many samples with a high
population in the region corresponding to R particles.
Figure 2 compares the Mw values of liver glycogen from
healthy (db/þ) and diabetic (db/db) mice aged 3 months. It
is seen that adult db/db mouse liver consists of glycogen
molecules that have Mw ≈ 10
7 Da, a typical molecular weight
Figure 1. SEC weight distributions of mouse-liver glycogen from
various individual adult healthy (db/þ, blue, A; þ/þ, green, B) and
adult type 2 diabetic/obese (db/db, red, C) mice and from various
individual young db/db mice (which would later have become diabetic;
red) and young db/þ mice (which would not have become diabetic
later; blue) mouse-liver glycogen (D). The normalization of these
distributions is arbitrary and for convenience is chosen so that their
areas are unity. Identiﬁcation of individual mice are given in the
Supporting Information. Inserted in part A is a transmission electron
micrograph of mouse liver glycogen showing R and β particles. The
diameter of the R particle in the micrograph is ∼150 nm.
Figure 2. Mw values of mouse liver glycogen from various individual
healthy (db/þ, in blue) and type 2 diabetic (db/db, in red) mice aged 3
months. Identiﬁcation of individual mice in the Supporting Information
(Figure S4).1985 dx.doi.org/10.1021/bm2006054 |Biomacromolecules 2011, 12, 1983–1986
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for β particles. However, db/þ (healthy) mouse liver glycogen
can contain much larger particles, with Mw as large as ∼10 times
that of typical β particles (the latter exempliﬁed in Figure 4 of
Sullivan et al.
11), indicating that there is a signiﬁcant number of
R particles. Consistent with Figure 1, db/þ glycogen also shows
a much greater range of average Mw values, with one sample
having Mw ≈ 10
7 Da, corresponding to the molecular weight of
β particles.
The mice in this study had free access to food and water at all
times. Each size distribution therefore eﬀectively is a snapshot at
diﬀerent times after feeding. Healthy mouse livers have some
distributionscontainingahighproportionoflargemoleculesand
others primarily of small molecules. Glycogen isolated from
db/db mice has little variation between samples, suggesting that
large R particles are unable to form. This diﬀerence between
healthy and diabetic/obese mice, as evaluated bythe values ofRh
at the maximum in each distribution and by the values of Mw,i s
statistically valid (P < 0.05). All results were expressed as the
mean(standarddeviation,withstatisticalsigniﬁcanceevaluated
with the nonparametric Kruskal Wallis test, followed by the
Mann Whitney test (Supporting Information).
In principle, this diﬀerence in glycogen from db/db and
healthy mice, inferred from the SEC distributions, could be
veriﬁed by quantitative electron microscopy. However, in prac-
tice, this is not straightforward. To avoid artifacts, quantiﬁcation
of size distributionsin heterogeneous systems from transmission
electron microscopy, even in simple systems such as polymer
colloids, requires thousands of particles in a large number of
individual images chosen randomly on the TEM grid.
14 Quanti-
tative transmission electron microscopy of these glycogen sys-
tems is a signiﬁcant area for future work.
The db/db mice used in this study are genetically modiﬁed to
express a malfunctioning leptin receptor (which governs satiety)
and therefore become obese. Figure 1D shows the SEC weight
distributions of young (1.5 months old) db/db and db/þ mice.
Thisexperiment was performedto see ifthe changes in glycogen
structureobservedindb/dbmiceoccurbeforetheonsetoftype2
diabetes/obesity or are due to the change of leptin receptor
per se. The young db/db mice would have become diabetic as
they grew older but were not diabetic at the time of sacriﬁce.
Figure 3 shows the chain-length distributions of adult db/db
and db/þ mouse-liver glycogen at the age of 3 months. Con-
tamination of glycogen by small oligosaccharides at DP X below
∼10 prevented the comparison of smaller chain lengths. The
slopesoftheclearlylinearregionsovertherange18eXe27are
 0.27 ( 0.03 for db/db and  0.23 ( 0.009 for db/þ. This
observation that the absolute values of the slopes of healthy
glycogenbranchesforhighDParevery slightlylessthanthoseof
db/db suggests that healthy glycogen contains a slightly higher
proportion of large chains than db/db (for example,
15 that the
relativenumberofbranchesbetween,say,20eXe30,isslightly
less than that above 30 for healthy compared with db/db).
’DISCUSSION
The results indicate that before the onset of the physiological
conditions associated with db/db mice, such as obesity and high
blood-glucose levels, large glycogen molecules (including R
particles) are still able to form. This suggests that the structural
diﬀerences between glycogen in db/db compared with healthy
mice arise from physiological changes associated with obesity,
type 2 diabetes, or both and not simply from the leptin receptor
mutation.
The nature of the (sub)structures of R and β particles and the
nature of the bond between the β particles in R particles has not
yet been elucidated. The basic glycogen synthesis enzymes are
the primer (which for animals is glycogenin), glycogen synthase,
andglycogenbranchingenzyme.AqualitativelysimilarRparticle
structure is seen in both (animal) liver glycogen and (plant)
phytoglycogen,
2 suggesting that whatever the binding is, it may
arisefromthesebasicglycogensynthesisenzymesratherthan(as
we had previously suggested
11) from some additional enzyme
present in hepatocytes. There are indications
11 that the bond
betweentheβparticlesinRparticlesisprobablychemical;inthe
same study, theoretical ﬁtting to the same type of size distribu-
tions as determined here indicated that R particles comprise
randomlylinkedassemblagesofβparticles.Ithasbeensuggested
from simulation that glycogen is arranged in tiers and that these
are self-limiting in size beyond 12 tiers.
16 This would provide a
mechanismfortheassemblyofRparticlesifnewβsubunitswere
formed by a budding process arising from this self-limiting step;
however, this hypothesis also implies that the number size
distribution of β particles in systems without R particles should
show a maximum corresponding to this size, but this is not
observed experimentally.
11 The mechanism for the formation of
R particles is thus not yet clear.
One possible reason that type 2 diabetic mice are not able to
form large R particles may be due to an increase in primer
(glycogenin) levels. Overexpression of glycogenin in rat-1 ﬁbro-
blasts does not increase the overall glycogen content but results
in a distribution of smaller glycogen particles.
17
’CONCLUSIONS
The data indicate that the synthesis of larger R particles of
glycogen is impaired in livers of adult db/db mice; support for
this inference can be discerned in previous size data obtained by
sucrose density centrifugation,
18 although that technique cannot
give quantitative size distributions.
This result can be rationalized as follows. The R particles
comprise tightly linked β particles, and the space between these
linkedβparticlesissigniﬁcantlylessthanthattypicalofenzymes.
This compact structure and large size would be likely to result in
Figure 3. Chain-length distributions of db/þ (blue) and db/db (red)
mouse-liver glycogen from FACE. The normalization of the distribu-
tions is arbitrary, and, for visual clarity, these have been chosen to give
adequate vertical separation of each ln Nde(X). Identiﬁcation of indivi-
dual mice in the Supporting Information.1986 dx.doi.org/10.1021/bm2006054 |Biomacromolecules 2011, 12, 1983–1986
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slower glucose release (per monomer unit) under hypoglycemic
conditions than would the smaller β particles, which are more
accessible per monomer unit to the glycogen degradation
enzymes. (Note that this concerns glycogen degradation, not
its synthesis, which creates the particles in the ﬁrst place.) Rapid
glucose release is desirable in the muscles, wherein the glycogen
is composedentirelyof βparticles but can lead tohyperglycemia
if poorly controlled, which is likely to be the case when the slow-
release mechanism of R particles in the liver is impaired. This
poor glucosecontrol canimpacttheuncontrolledhyperglycemia
that typiﬁes diabetes.
The observation of impaired R-particle formation in db/db
mice is statistically valid in the data set given here, which has
fundamental physiological implications in glycogen biosynth-
esis/degradation cycles. There is a long list of experiments that
shouldbeundertaken toexplore this result, including: increasing
thenumberofsamplesforhigherstatisticalconﬁdence;perform-
ing measurements with sacriﬁces at controlled feeding quantities
and times; examining the correlation of type 2 diabetes with
glycogenstructurebyusingothertype2diabeticmodelssuchasa
high-fat-diet induced type 2 diabetic mouse model; performing
corresponding experiments with Akita mice and other type
1 diabetic mouse models; and comparing the levels of glyc-
ogenin and other enzymes involved in glycogen synthesis and
degradation in type 2 diabetic, type 1 diabetic, and nondiabetic
mouse liver.
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